The decline in Lexeo Therapeutics' stock price can be attributed to the market's reaction to its Q4 financial results, which may have not met investor expectations. Additionally, while securing $95 million in equity financing is positive for the company's capital, the oversubscription might raise concerns about dilution or the company's valuation, further impacting the stock negatively in the short term.